FINWIRES · TerminalLIVE
FINWIRES

Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says

By

Neurocrine Biosciences' (NBIX) Ingrezza sales momentum could support a 2026 guidance increase, while Vykat growth is expected to slow and major pipeline data are not expected before the second half of 2027, UBS Securities said.

The investment firm raised its 2026 Ingrezza sales estimate to $2.80 billion from $2.75 billion, slightly above the $2.78 billion consensus forecast. UBS said changes in insurance coverage for Teva's (TEVA) Austedo could favor Ingrezza, while Neurocrine's roughly 30% expansion of its sales force should provide additional support.

UBS expects Vykat sales growth to slow after strong early demand, forecasting 2026 sales of $235 million, below the $294 million consensus estimate. The brokerage projects peak sales of $616 million, well below the $1.36 billion consensus forecast, reflecting slower patient additions and a higher expected treatment discontinuation rate.

The firm said major data from three phase 3 trials of osavampator in major depressive disorder and the first phase 3 trial of direclidine in schizophrenia are not expected until the second half of 2027, leaving few significant clinical catalysts before then.

UBS maintained its buy rating on Neurocrine and raised its price target to $208 from $182.

Price: $169.99, Change: $-0.01, Percent Change: -0.01%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC